In response to the recent changes (COVID-19 pandemic, precision medicine, increased healthcare expenditure, expanded use of real-world data), healthcare decision-making bodies searched for new ways to implement more responsive, innovative processes for the technologies’ assessment. These changes along the increased recognition of current HTA challenges (evidence availability and quickly out of date evidence reviews, health care system sustainability, budgetary constraints) have opened a window of opportunity for decision makers to consider moving towards a fully, “living” approach to health technology assessment (HTA). Furthermore, these challenges are even magnified in the context of a general drive for faster patient access to effective health technologies.

This theatre will discuss how the traditional methods for synthesizing comparative clinical and economic evidence for the assessment of new health technologies may be problematic and how the exploration of more reactive and flexible “liveHTA” approaches can mitigate these challenges. The speakers will also discuss implementation tools to make liveHTA a reality for health care decision-makers.